

LIST OF TABLES

Sr. No.	Topic	Page No.
Table 2.1	The Lipid Formulation Classification System: characteristic features, pros and cons of the four essential types of 'lipid' formulations	41
Table 2.2	Properties of Asenapine maleate	52
Table 2.3	Properties of Lurasidone HCl	57
Table 2.4	Properties of GMS	61
Table 2.5	Properties of Pluronic F-68	63
Table 2.6	Uses of Poloxamer	66
Table 2.7	Properties of Capmul MCM C8	66
Table 2.8	Properties of Polyoxyl 35 castor oil	68
Table 2.9	LD ₅₀ value of cremophor EL	69
Table 2.10	Properties of Propylene glycol monocaprylate	71
Table 2.11	Properties of diethylene glycol monoethyl ether	72
Table 2.12	Properties of Sodium deoxycholate	73
Table 2.13	Properties of TPGS	74
Table 3.1	Standard Calibration data of Asenapine maleate in Methanol	94
Table 3.2	Regression analysis of Asenapine maleate in methanol	96
Table 3.3	Accuracy and precision for Asenapine maleate in methanol	96
Table 3.4	Standard Calibration data of Asenapine maleate in Chloroform: Methanol	97
Table 3.5	Regression analysis of Asenapine maleate in chloroform:methanol	98
Table 3.6	Accuracy and precision for Asenapine maleate in chloroform:methanol	99
Table 3.7	Standard Calibration data of Asenapine maleate in 0.1 N HCl	99
Table 3.8	Regression analysis of Asenapine maleate in 0.1 N HCl	101
Table 3.9	Accuracy and precision for Asenapine maleate in 0.1 N HCl	101
Table 3.10	Standard Calibration data of Asenapine maleate in phosphate buffer pH 6.8	102

Table 3.11	Regression analysis of Asenapine maleate in phosphate buffer pH 6.8	103
Table 3.12	Accuracy and precision for Asenapine maleate in phosphate buffer pH 6.8	104
Table 3.13	Standard Calibration data of Asenapine maleate in phosphate buffer pH 7.4	104
Table 3.14	Regression analysis of Asenapine maleate in phosphate buffer pH 7.4	106
Table 3.15	Accuracy and precision for Asenapine maleate in phosphate buffer pH 7.4	106
Table 3.16	Standard Calibration data for estimation of Asenapine maleate in buffer:ACN	107
Table 3.17	Regression analysis of Asenapine maleate in phosphate buffer:ACN	108
Table 3.18	Accuracy and precision for Asenapine maleate in phosphate buffer:ACN	109
Table 3.19	Standard Calibration data for estimation of Asenapine maleate in plasma	109
Table 3.20	Regression analysis of Asenapine maleate in plasma	111
Table 3.21	Accuracy and precision for Asenapine maleate in plasma	111
Table 3.22	Standard Calibration data of Lurasidone HCl in Methanol	112
Table 3.23	Regression analysis of Lurasidone HCl in Methanol	113
Table 3.24	Accuracy and precision for Lurasidone HCl in Methanol	114
Table 3.25	Standard Calibration data of Lurasidone HCl in Chloroform:Methanol	114
Table 3.26	Regression analysis of Lurasidone HCl in Chlorofom:Methanol	116
Table 3.27	Accuracy and precision of Lurasidone HCl in Chlorofom:Methanol	116
Table 3.28	Standard Calibration data of Lurasidone HCl in 0.1 N HCl	117
Table 3.29	Regression analysis of Lurasidone HCl in 0.1N HCl	118
Table 3.30	Accuracy and precision for Lurasidone HCl in 0.1N HCl	119

Table 3.31	Standard Calibration data of Lurasidone HCl in phosphate buffer pH 6.8	119
Table 3.32	Regression analysis of Lurasidone HCl in phosphate buffer pH 6.8	121
Table 3.33	Accuracy and precision for Lurasidone HCl in phosphate buffer pH 6.8	121
Table 3.34	Standard Calibration data of Lurasidone HCl in phosphate buffer pH 7.4	122
Table 3.35	Regression analysis of Lurasidone HCl in phosphate buffer pH 7.4	124
Table 3.36	Accuracy and precision for Lurasidone HCl in phosphate buffer pH 7.4	124
Table 3.37	Standard Calibration data for estimation of Lurasidone HCl in phosphate buffer:ACN	125
Table 3.38	Regression analysis of Lurasidone HCl in Phosphate buffer:ACN	126
Table 3.39	Accuracy and precision for Lurasidone HCl in Phosphate buffer:ACN	127
Table 3.40	Standard Calibration data for estimation of Lurasidone HCl in Plasma	127
Table 3.41	Regression analysis of Lurasidone HCl in plasma	129
Table 3.42	Accuracy and precision for Lurasidone HCl in plasma	129
Table 4.1	The coded and actual values of independent variables of AM-SLNs	134
Table 4.2	Various release kinetic models	138
Table 4.3	Effect of homogenization speed on particle size and entrapment efficiency of AM-SLNs	142
Table 4.4	Effect of homogenization time on particle size and entrapment efficiency of AM-SLNs	143
Table 4.5	Effect of sonication time on particle size and entrapment efficiency of AM-SLNs	144
Table 4.6	Effect of Sonication amplitude on particle size and entrapment efficiency of AM-SLNs	144

Table 4.7	Effect of lipid concentration on particle size and entrapment efficiency of AM-SLNs	145
Table 4.8	Effect of surfactant concentration on particle size and entrapment efficiency of AM-SLNs	146
Table 4.9	Effect of type of lipid on particle size and entrapment efficiency of AM-SLNs	146
Table 4.10	Effect of type of surfactant on particle size and entrapment efficiency of AM-SLNs	147
Table 4.11	Effect of TPGS concentration on particle size and entrapment efficiency of AM-SLNs	148
Table 4.12	Values of variables selected for PBD after preliminary optimization of AM-SLNs	148
Table 4.13	PBD experimental runs of AM-SLNs	149
Table 4.14	Estimated effects and coefficients for particle size (coded units) of AM-SLNs	150
Table 4.15	Estimated effects and coefficients for entrapment efficiency (coded units) of AM-SLNs	153
Table 4.16	Central composite design experimental runs of AM-SLNs	156
Table 4.17	Effect tests analysis of independent variables on particle size of AM-SLNs	157
Table 4.18	Effect tests analysis of independent variables on entrapment efficiency of AM-SLNs	160
Table 4.19	Predicted and experimental value of optimized batch of AM-SLNs suggested by software	163
Table 4.20	Evaluation of sensitivity of obtained design space for AM-SLNs	164
Table 4.21	Optimization of cryoprotectants of AM-SLNs	167
Table 4.22	Correlation coefficient value of AM release kinetics	175
Table 4.23	Characteristics of AM-SLNs after 3-months stability studies at different conditions	177
Table 5.1	The coded and actual values of independent variables for AM- SMEDDS	184

Table 5.2	Classification of the SMEDDS Formulation in Accordance to Comparative Grades	186
Table 5.3	D-optimal design runs of AM-SMEDDS	196
Table 5.4	ANOVA analysis for globule size of AM-SMEDDS	197
Table 5.5	ANOVA analysis for % transmittance of AM-SMEDDS	200
Table 5.6	ANOVA analysis for self-emulsification time of AM-SMEDDS	204
Table 5.7	Regression analysis for all responses of AM-SMEDDS	208
Table 5.8	Predicted and observed responses for check point batch of AM-SMEDDS	208
Table 5.9	Evaluation of sensitivity of obtained design space of AM-SMEDDS	209
Table 5.10	Robustness to dilution of AM-SMEDDS with different media	212
Table 5.11	Characteristics of AM-SMEDDS after 3-months stability studies at different conditions	217
Table 6.1	The coded and actual values of independent variables of LH-SLNs	226
Table 6.2	Effect of homogenization speed on particle size and entrapment efficiency of LH-SLNs	231
Table 6.3	Effect of homogenization time on particle size and entrapment efficiency of LH-SLNs	232
Table 6.4	Effect of homogenization pressure on particle size and entrapment efficiency of LH-SLNs	233
Table 6.5	Effect of homogenization cycle on particle size and entrapment efficiency of LH-SLNs	233
Table 6.6	Effect of lipid concentration on particle size and entrapment efficiency of LH-SLNs	234
Table 6.7	Effect of surfactant concentration on particle size and entrapment efficiency of LH-SLNs	235
Table 6.8	Effect of type of surfactant on particle size and entrapment efficiency of LH-SLNs	236

Table 6.9	Effect of sodium Deoxycholate concentration on particle size and entrapment efficiency of LH-SLNs	236
Table 6.10	Values of variables selected for PBD after preliminary optimization of LH-SLNs	237
Table 6.11	PBD experimental runs of LH- SLNs	238
Table 6.12	Estimated effects and coefficients for particle size (coded units) of LH-SLNs	239
Table 6.13	Estimated effects and coefficients for entrapment efficiency (coded units) of LH-SLNs	242
Table 6.14	Box Behnken Design experimental runs of LH-SLNs	245
Table 6.15	Effect tests analysis of independent variables on particle size of LH-SLNs	246
Table 6.16	Effect tests analysis of independent variables on entrapment efficiency of LH-SLNs	248
Table 6.17	Predicted and observed responses for check point batch of LH-SLNs	251
Table 6.18	Evaluation of sensitivity of obtained design space of LH-SLNs	252
Table 6.19	Optimization of cryoprotectants of LH-SLNs	255
Table 6.20	Correlation coefficient value of LH release kinetics	263
Table 6.21	Characteristics of LH-SLNs after 3-months stability studies at different conditions	265
Table 7.1	The coded and actual values of independent variables of LH-SMEDDS	271
Table 7.2	3 ² factorial design runs of LH-SMEDDS	279
Table 7.3	Results of ANOVA for globule size of LH-SMEDDS	280
Table 7.4	Results of ANOVA for percentage transmittance of LH-SMEDDS	282
Table 7.5	Results of ANOVA for self-emulsification time of LH-SMEDDS	283
Table 7.6	Regression analysis for all responses of LH-SMEDDS	285
Table 7.7	Predicted and observed responses for check point batch of LH-SMEDDS	285

Table 7.8	Evaluation of sensitivity of obtained design space of LH-SMEDDS	286
Table 7.9	Robustness to dilution with different media of LH-SMEDDS	289
Table 7.10	Characteristics of LH-SMEDDS after 3-months stability study	294
Table 8.1	Drug transfer across the Caco-2 cell line for AM-SLNs, AM-SMEDDS and AM suspension	326
Table 8.2	Apparent permeability (P _{app}) and enhancement ratio of AM suspension, AM-SLNs and AM-SMEDDS	327
Table 8.3	Drug transfer across the Caco-2 cell line for LH-SLNs, LH-SMEDDS and LH suspension	328
Table 8.4	Apparent permeability (P _{app}) and enhancement ratio of LH suspension, LH-SLNs and LH-SMEDDS	328
Table 9.1	Behavioral scores for MK-801-induced locomotion, stereotypy and ataxia in rats	339
Table 9.2	Pharmacokinetic parameters of AM-SLNs and AM suspension after oral administration	341
Table 9.3	Pharmacokinetic parameters of LH-SLNs and LH suspension after oral administration.	343
Table 9.4	Pharmacokinetic parameters of AM-SMEDDS and AM suspension after oral administration	345
Table 9.5	Pharmacokinetic parameters of LH-SMEDDS and LH suspension after oral administration	347